Nextcure Stock Cash And Equivalents
| NXTC Stock | USD 1.67 0.02 1.21% |
NextCure fundamentals help investors to digest information that contributes to NextCure's financial success or failures. It also enables traders to predict the movement of NextCure Stock. The fundamental analysis module provides a way to measure NextCure's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NextCure stock.
NextCure | Cash And Equivalents |
NextCure Company Cash And Equivalents Analysis
NextCure's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current NextCure Cash And Equivalents | 185.49 M |
Most of NextCure's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NextCure is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NextCure Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for NextCure is extremely important. It helps to project a fair market value of NextCure Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since NextCure's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NextCure's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NextCure's interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
NextCure Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, NextCure has 185.49 M in Cash And Equivalents. This is 77.4% lower than that of the Biotechnology sector and 58.51% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 93.14% higher than that of the company.
NextCure Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NextCure's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NextCure could also be used in its relative valuation, which is a method of valuing NextCure by comparing valuation metrics of similar companies.NextCure is currently under evaluation in cash and equivalents category among related companies.
NextCure Current Valuation Drivers
We derive many important indicators used in calculating different scores of NextCure from analyzing NextCure's financial statements. These drivers represent accounts that assess NextCure's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of NextCure's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 65.2M | 855.2M | 270.8M | 19.6M | 25.3M | 24.0M |
NextCure Fundamentals
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | (60.12 M) | ||||
| Shares Outstanding | 27.97 M | ||||
| Shares Owned By Insiders | 8.81 % | ||||
| Shares Owned By Institutions | 51.65 % | ||||
| Number Of Shares Shorted | 112.44 K | ||||
| Price To Earning | (25.44) X | ||||
| Price To Book | 0.47 X | ||||
| Price To Sales | 9.52 X | ||||
| Gross Profit | (54.2 M) | ||||
| EBITDA | (63.95 M) | ||||
| Net Income | (62.72 M) | ||||
| Cash And Equivalents | 185.49 M | ||||
| Cash Per Share | 6.68 X | ||||
| Total Debt | 6.61 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 33.87 X | ||||
| Book Value Per Share | 4.10 X | ||||
| Cash Flow From Operations | (52.97 M) | ||||
| Short Ratio | 0.26 X | ||||
| Earnings Per Share | (2.25) X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 82 | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 46.72 M | ||||
| Total Asset | 129.42 M | ||||
| Retained Earnings | (324.48 M) | ||||
| Working Capital | 105.84 M | ||||
| Current Asset | 46.99 M | ||||
| Current Liabilities | 5.53 M | ||||
| Net Asset | 129.42 M |
About NextCure Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NextCure's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NextCure using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NextCure based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock:Check out NextCure Piotroski F Score and NextCure Altman Z Score analysis. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for NextCure Stock analysis
When running NextCure's price analysis, check to measure NextCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCure is operating at the current time. Most of NextCure's value examination focuses on studying past and present price action to predict the probability of NextCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCure's price. Additionally, you may evaluate how the addition of NextCure to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is NextCure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.25) | Quarterly Revenue Growth (1.00) | Return On Assets (0.27) | Return On Equity (0.44) |
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.